Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Oct. 18, 2012

FDA Should Reject Dangerous Cholesterol Medication, Public Citizen Tells Advisory Committee

Mipomersen, Studied in an Unethical Clinical Trial, Shown to Cause a Plethora of Side Effects

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve the proposed cholesterol drug mipomersen because the study supporting approval was unethical and withheld an effective therapy from patients with a rare disease, Public Citizen said today in testimony to the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee.

Mipomersen is the first of a new class of drugs developed to treat homozygous familial hypercholesterolemia (HoFH), an extremely rare, fatal genetic condition that leads to very high blood cholesterol levels.

However, Public Citizen testified that the pivotal trial conducted in HoFH patients to support the drug’s approval was unethical because investigators withheld an effective, standard, life-prolonging treatment – LDL apheresis – from all patients.

This and other trials also showed that mipomersen caused liver damage, flu-like symptoms and possibly cancer in a large number of patients, according to FDA reviewers. Mostly due to these side effects, more than half of the HoFH patients stopped taking mipomersen before the trial was completed. But because the drug stays in the bloodstream long after discontinuation, side effects continued in many HoFH and other patients for several months afterwards.

Of further concern, animal studies also demonstrated that the drug is carcinogenic at doses close to those that would be used in human patients.

“In the zeal to demonstrate mipomersen to be effective, the trial excluded the use of a known beneficial treatment, LDL apheresis,” said Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group. “It will be interesting to find out how the institutional review boards overseeing this trial (or the FDA) allowed it to go forward. Until a more ethical trial is conducted, with more encouraging safety results, the drug should certainly not be approved.”

To read today’s testimony, please visit http://www.citizen.org/hrg2079.

 

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.